Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma

Claudio Cerchione, MD PhD, Lucio Catalano, Davide Nappi, Anna Emanuele Pareto, Gerardo Musuraca, MD, Alessandro Lucchesi, MD, Sonia Ronconi, Michela Ceccolini, MD, Delia Cangini, Maria Benedetta Giannini, MD, Valeria Di Battista, Giorgia Simonetti, PhD, Andrea Ghelli Luserna Di Rorà, PhD, Fabrizio Pane, Giovanni Martinelli, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-143143

Published: 2020

Journal Articles

The Prolonged Inhibition of Chk1/Chk2 Kinases Enhances Genetic Instability and Compromises the Efficacy of Chemotherapy Against Acute Lymphoblastic Leukemia Cells

Andrea Ghelli Luserna Di Rorà, PhD, Antonella Padella, PhD, Maria Chiara Fontana, PhD, Eugenio Fonzi, PhD, Anna Ferrari, PhD, Enrica Imbrogno, PhD, Martina Ghetti, PhD, Roberta Napolitano, PhD, Maria Teresa Bochicchio, Giovanni Martinelli, MD, Giorgia Simonetti, PhD

Blood (2019) 134 (Supplement_1): 5047.

https://doi.org/10.1182/blood-2019-129964

Published: 2019

Journal Articles

Higher Expression of PALB2 Predict Poor Prognosis in AML Patients and Identifies Potential Targets of Synthetic Lethal Therapies

Antonella Padella, Giovanni Marconi, Giorgia Simonetti, PhD, Andrea Ghelli Luserna Di Rora, Maria Chiara Fontana, MSc, Cristina Papayannidis, Emanuela Ottaviani, Michele Cavo, MD, Simona Soverini, PhD, Giovanni Martinelli

Blood (2018) 132 (Supplement 1): 1507.

https://doi.org/10.1182/blood-2018-99-118210

Published: 2018

Journal Articles

A New Gene Expression Profile Signature CRLF2 Overexpression Based Identifies Novel Adult "Triple Negative" Acute Lymphoblastic Leukemia Subgroups

Blood (2018) 132 (Supplement 1): 5284.

https://doi.org/10.1182/blood-2018-99-118062

Published: 2018

Journal Articles

Targeting a Specific Glycosylated Epitope of CD43 with a New Humanized Monoclonal Antibody for the Treatment of Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Cirino Botta, MD, Giuseppe Gaipa, PhD, Maria Eugenia Gallo Cantafio, PhD, Chiara Buracchi, PhD, Maria Anna Siciliano, MD, Caterina Riillo, MD, Katia Grillone, PhD, Alessandro Gulino, Maria Cucè, Nicoletta Staropoli, Andrea Ghelli Luserna Di Rora, Franca Maria Tuccillo, Maria Teresa Di Martino, Claudio Tripodo, MD, Marco Rossi, MD, Giovanni Martinelli, Andrea Biondi, MD, Pierosandro Tagliaferri, Pierfrancesco Tassone, MD

Blood (2018) 132 (Supplement 1): 1418.

https://doi.org/10.1182/blood-2018-99-118572

Published: 2018

Journal Articles

MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration

Giovanni Marconi, MD, Maria Chiara Fontana, MSc, Eugenio Fonzi, PhD, Cristina Papayannidis, MD, Mariachiara Abbenante, MD, Emanuela Ottaviani, Nicoletta Testoni, BSc, Giorgia Simonetti, PhD, Antonella Padella, Chiara Sartor, Carmen Baldazzi, Jacopo Nanni, MD, Luca Bertamini, MD, Andrea Ghelli Luserna Di Rora, Valentina Robustelli, Martina Pazzaglia, Elena Tenti, PhD, Sarah Parisi, MD PhD, Giovanni Martinelli, MD

Blood (2017) 130 (Supplement 1): 3958.

https://doi.org/10.1182/blood.V130.Suppl_1.3958.3958

Published: 2017

Journal Articles

Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization

Blood (2017) 130 (Supplement 1): 2720.

https://doi.org/10.1182/blood.V130.Suppl_1.2720.2720

Published: 2017

Journal Articles

Enhance the Efficacy of Doxorubicin Destabilizing the G2/M Checkpoint with a CHK1/CHK2 Inhibitor Pre-Treatment on Acute Lymphoblastic Leukemia

Andrea Ghelli Luserna di Rora', Anna Ferrari, PhD, Enrica Imbrogno, Valentina Robustelli, Cristina Papayannidis, MD, maria Chiara Abbenante, Giovanni Marconi, MD, Michele Cavo, MD, Giovanni Martinelli, MD

Blood (2017) 130 (Supplement 1): 5049.

https://doi.org/10.1182/blood.V130.Suppl_1.5049.5049

Published: 2017

Journal Articles

Mine the Stability of the G2/M Checkpoint to Break Down Acute Lymphoblastic Leukemia Defenses Against Antineoplastic Drugs

Andrea Ghelli Luserna di Rorà, Ilaria Iacobucci, PhD, Neil Beeharry, Maria Vittoria Falzacappa, Chiara Ronchini, Cristina Papayannidis, MD PhD, Enrica Imbrogno, Anna Ferrari, PhD, Valentina Robustelli, Antonella Padella, Giovanni Martinelli, Timothy Yen

Blood (2016) 128 (22): 2808.

https://doi.org/10.1182/blood.V128.22.2808.2808

Published: 2016

Journal Articles

Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations

Blood (2016) 128 (22): 1678.

https://doi.org/10.1182/blood.V128.22.1678.1678

Published: 2016

Journal Articles

Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML)

Blood (2016) 128 (22): 1679.

https://doi.org/10.1182/blood.V128.22.1679.1679

Published: 2016

Journal Articles

Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience

Blood (2016) 128 (22): 5191.

https://doi.org/10.1182/blood.V128.22.5191.5191

Published: 2016

Journal Articles

The Wee1 Inhibitor, MK-1775, Sensitizes Leukemic Cells to Different Antineoplastic Drugs Interfering with DNA Damage Response Pathway

Andrea Ghelli Luserna Di Rora, Ilaria Iacobucci, PhD, Neil Beeharry, Simona Soverini, Cristina Papayannidis, MD PhD, Giovanni Martinelli, MD PhD, Timothy J Yen

Blood (2015) 126 (23): 1276.

https://doi.org/10.1182/blood.V126.23.1276.1276

Published: 2015

Journal Articles

Clustering Adult ACUTE Lymphoblastic Leukemia (ALL) Philadelphia Negative (Ph-) By Whole Exome Sequencing (WES) Analysis

Blood (2015) 126 (23): 2623.

https://doi.org/10.1182/blood.V126.23.2623.2623

Published: 2015

Journal Articles

The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia

Andrea Ghelli Luserna Di Rora, Ilaria Iacobucci, PhD, Enrica Imbrogno, Enrico Derenzini, MD, Anna Ferrari, PhD, Viviana Guadagnuolo, PhD, Valentina Robustelli, Simona Soverini, Cristina Papayannidis, MD PhD, Maria Chiara Abbenante, MD, Michele Cavo, MD, Giovanni Martinelli, MD PhD

Blood (2015) 126 (23): 2478.

https://doi.org/10.1182/blood.V126.23.2478.2478

Published: 2015

Journal Articles

Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience

Blood (2013) 122 (21): 3911.

https://doi.org/10.1182/blood.V122.21.3911.3911

Published: 2013

Journal Articles

Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis

Blood (2013) 122 (21): 2622.

https://doi.org/10.1182/blood.V122.21.2622.2622

Published: 2013

NARROW

Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma

The Prolonged Inhibition of Chk1/Chk2 Kinases Enhances Genetic Instability and Compromises the Efficacy of Chemotherapy Against Acute Lymphoblastic Leukemia Cells

Higher Expression of PALB2 Predict Poor Prognosis in AML Patients and Identifies Potential Targets of Synthetic Lethal Therapies

A New Gene Expression Profile Signature CRLF2 Overexpression Based Identifies Novel Adult "Triple Negative" Acute Lymphoblastic Leukemia Subgroups

Targeting a Specific Glycosylated Epitope of CD43 with a New Humanized Monoclonal Antibody for the Treatment of Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)

MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration

Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization

Enhance the Efficacy of Doxorubicin Destabilizing the G2/M Checkpoint with a CHK1/CHK2 Inhibitor Pre-Treatment on Acute Lymphoblastic Leukemia

Mine the Stability of the G2/M Checkpoint to Break Down Acute Lymphoblastic Leukemia Defenses Against Antineoplastic Drugs

Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations

Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML)

Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience

The Wee1 Inhibitor, MK-1775, Sensitizes Leukemic Cells to Different Antineoplastic Drugs Interfering with DNA Damage Response Pathway

Clustering Adult ACUTE Lymphoblastic Leukemia (ALL) Philadelphia Negative (Ph-) By Whole Exome Sequencing (WES) Analysis

The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia

Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience

Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only